| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6635280 | MSD SUB MERCK | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6340475 | MSD SUB MERCK | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6303661 | MSD SUB MERCK | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
| US6890898 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7078381 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7459428 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7125873 | MSD SUB MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
|
US7125873 (Pediatric) | MSD SUB MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 3 months ago) | |
|
US6699871 (Pediatric) | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 3 months ago) | |
|
US7326708 (Pediatric) | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
Janumet Xr is owned by Msd Sub Merck.
Janumet Xr contains Metformin Hydrochloride; Sitagliptin Phosphate.
Janumet Xr has a total of 12 drug patents out of which 10 drug patents have expired.
Expired drug patents of Janumet Xr are:
- US6635280
- US6340475
- US6303661
- US6890898
- US7078381
- US7459428
- US7125873
- US7125873*PED
- US6699871*PED
- US6699871
Janumet Xr was authorised for market use on 02 February, 2012.
Janumet Xr is available in tablet, extended release;oral dosage forms.
Janumet Xr can be used as method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate, improvement of glycemic control in adults with type 2 diabetes mellitus.
The generics of Janumet Xr are possible to be released after 24 May, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Feb 12, 2023 |
| M(M-244) | Aug 12, 2022 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 02 February, 2012
Treatment: Improvement of glycemic control in adults with type 2 diabetes mellitus; Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended rel...
Dosage: TABLET, EXTENDED RELEASE;ORAL
JANUMET XR family patents
